New Molecule Targets Glioblastoma at Its Genetic Root

Researchers at the University of Virginia Comprehensive Cancer Center have identified a small molecule that disrupts the activity of the AVIL gene, a critical oncogene associated with glioblastoma, an aggressive form of brain cancer. This discovery, detailed in a study published in *Science Translational Medicine*, marks a significant advancement in the search for effective treatments for a disease that currently has limited therapeutic options. Glioblastoma is known for its rapid growth and high mortality rate, with an average survival time of about 15 months post-diagnosis.

SciTechDaily

The newly identified molecule effectively blocks the AVIL gene's activity in both laboratory cell samples and mouse models, demonstrating the potential to target tumor cells while sparing healthy brain tissue. This is particularly important as glioblastoma cells infiltrate surrounding brain areas, making complete surgical removal challenging. Previous methods to inhibit AVIL were impractical for human application, prompting researchers to seek a more viable drug-like molecule. The compound can be administered orally, similar to conventional medications, and has shown no harmful side effects in initial testing.

SciTechDaily

Utilizing high-throughput screening techniques, the research team evaluated numerous compounds to find one capable of interrupting AVIL's harmful effects. The AVIL protein is rarely found in healthy human brains but is abundant in glioblastoma patients, confirming its role in the disease's progression. The researchers emphasize that while the findings are promising, extensive further research is necessary to optimize the molecule for human use and to conduct safety and efficacy trials before seeking approval from the U.S. Food and Drug Administration.

SciTechDaily

Hui Li, PhD, the lead researcher, highlighted the urgent need for improved treatment options for glioblastoma patients, stating, “Standard therapy hasn’t fundamentally changed in decades, and survival remains dismal.” The goal of this research is to introduce a novel mechanism of action that targets a core vulnerability in glioblastoma biology, potentially transforming the treatment landscape for this devastating disease.

SciTechDaily

The research received funding from the National Institutes of Health and the Ben & Catherine Ivy Foundation. In addition, Li has established a company, AVIL Therapeutics, to further develop AVIL inhibitors and has secured a patent related to this innovative approach. As the research progresses, the team remains optimistic about the potential impact of their findings on glioblastoma treatment.

SciTechDaily

• “Glioblastoma is a devastating disease. Essentially, no effective therapy exists,” — Hui Li, PhD, University of Virginia School of Medicine

SciTechDaily

• “GBM patients desperately need better options.” — Hui Li, PhD, University of Virginia School of Medicine

SciTechDaily

While the discovery of this small molecule represents a significant step forward in glioblastoma research, the path to clinical application will require rigorous testing and validation. The ongoing efforts by Li and his team could pave the way for a new era in the treatment of one of the most challenging cancers.

SciTechDaily